Evidence map›Paper›PMID 20368275›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2010

Docosahexaenoic acid-enriched fish oil attenuates kidney disease and prolongs median and maximal life span of autoimmune lupus-prone mice.

Ganesh V Halade, Md Mizanur Rahman, Arunabh Bhattacharya, Jeffrey L Barnes, Bysani Chandrasekar, Gabriel Fernandes

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Omega-3 Polyunsaturated Fatty Acids and Stroke Burden.International journal of molecular sciences · 2019
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ganesh V HaladeDivision of Clinical Immunology and Rheumatology, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA.
Md Mizanur Rahman
Arunabh Bhattacharya
Jeffrey L Barnes
Bysani Chandrasekar
Gabriel Fernandes
Center for Rheumatology · USTulane University · US

Funding

The Role of Interleukin-18 in Myocardial Hypertrophy and FailureR01HL086787 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BYSANI, CHANDRASEKAR · 2009 to 2013
$1.8M
Therapeutic Value of Fish Oil Rx on SLE and Bone Loss in MiceR01AT004259 · NCCIH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FERNANDES, GABRIEL J J · 2008 to 2012
$1.6M
Prolongation of lifespan by n-3 fatty acids and calorie restrictionR01AG030161 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FERNANDES, GABRIEL J J · 2008 to 2010
$818k
NCCIH NIH HHS 1R01AT004259-01NCCIH NIH HHS R01 AT004259NHLBI NIH HHS HL-86787NHLBI NIH HHS R01 HL086787NIA NIH HHS 1R01AG030161-01A1NIA NIH HHS R01 AG030161
6 · The paper itself

Abstract

The therapeutic efficacy of individual components of fish oils (FOs) in various human inflammatory diseases still remains unresolved, possibly due to low levels of n-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) or lower ratio of DHA to EPA. Because FO enriched with DHA (FO-DHA) or EPA (FO-EPA) has become available recently, we investigated their efficacy on survival and inflammatory kidney disease in a well-established animal model of human systemic lupus erythematosus. Results show for the first time that FO-DHA dramatically extends both the median (658 d) and maximal (848 d) life span of (NZB x NZW)F1 (B x W) mice. In contrast, FO-EPA fed mice had a median and maximal life span of approximately 384 and 500 d, respectively. Investigations into possible survival mechanisms revealed that FO-DHA (versus FO-EPA) lowers serum anti-dsDNA Abs, IgG deposition in kidneys, and proteinuria. Further, FO-DHA lowered LPS-mediated increases in serum IL-18 levels and caspase-1-dependent cleavage of pro-IL-18 to mature IL-18 in kidneys. Moreover, FO-DHA suppressed LPS-mediated PI3K, Akt, and NF-kappaB activations in kidney. These data indicate that DHA, but not EPA, is the most potent n-3 fatty acid that suppresses glomerulonephritis and extends life span of systemic lupus erythematosus-prone short-lived B x W mice, possibly via inhibition of IL-18 induction and IL-18-dependent signaling.

Indexed as

AnimalsAutoantibodiesCorn OilCrosses, GeneticDocosahexaenoic AcidsDrug SynergismEicosapentaenoic AcidFemaleFish OilsImmunoglobulin GInflammation MediatorsLongevityLupus Erythematosus, SystemicLupus NephritisMiceMice, Inbred NZBAutoantibodiesCorn OilDocosahexaenoic AcidsEicosapentaenoic AcidFish OilsImmunoglobulin GInflammation Mediators

Identifiers

PMID20368275
PMCPMC2952419
OpenAlexW2138880169

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.